Polymerase chain reaction (PCR) is certain to modify the approach to the diagnosis of viral hepatitis. While it provides a direct and highly sensitive identification of viral genomes, however, it has three important limitations: (a) the risk of false positive results because of contamination; (b) difficulties in developing quantitative tests; (c) the need for automisation and use of non-radioactive probes for wider availability of the technique. This review will discuss different clinical and practical uses of PCR for the diagnosis of viral hepatitis, focusing on the hepatitis B and C viruses.
PCR for the appraisal of viral multiplication HEPATITIS B VIRUS (HBV) Conventional hybridisation procedures have now been used widely for the detection of HBV-DNA in serum, tissues, and mononuclear blood cells."2 HBV-DNA is the most direct and sensitive test for viral multiplication and semiquantitative tests have been developed, based on liquid hybridisation.3'4
The limit of sensitivity, however, is 105-106 particles/ml of serum or plasma.
There is a need for more sensitive tests to identify the HBV-DNA sequences, based on the following: (a) hepatitis B surface antigen (HBsAg) positive blood donors or mothers have been shown to transmit HBV infection despite being positive for antibodies to hepatitis B e antigen (anti-HBe) and HBV-DNA negative in serum5'6; (b) some patients with HBsAg positive/anti-HBe positive chronic active hepatitis have active liver disease despite serum HBV-DNA negativity and absence of hepatitis delta virus or hepatitis C virus (HCV) coinfections, autoimmune liver disease, or other causes of liver disease; (c) it is important to have a precise follow up of patients under antiviral treatment, to evaluate partial or complete responses and the subsequent risk of reactivation; (d) PCR is necessary for subsequent sequencing of the amplified products (either direct sequencing or sequencing after cloning).2 It has provided information on the genetic variability of HBV and the potential implication of mutations in the pre-C, C, and pre-S/S viral sequences in the persistence of HBV infection, severity of liver disease, and response to treatment -`; (e) HBsAg negative patients with acute and chronic liver diseases have been shown to contain HBV-DNA sequences in the blood, liver, or mononuclear cells. HBV-DNA has also been shown in blood donors with no HBV serological marker.2 8
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The reliable detection and characterisation of these sequences is facilitated by PCR. detectable serum HCV-RNA; this suggests that PCR might allow the identification of individuals for further investigation and, possibly, treatment. It has also been found that anti-HCV negative subjects can be HCV-RNA positive. This has been shown both in patients with chronic hepatitis and in blood donors implicated in post-transfusional hepatitis.53 5 As for hepatitis B, HCV-RNA detection might be used in the future for the follow up of hepatitis C patients receiving treatment with interferon. Semiquantitative evaluation of HCV-RNA has been performed but is not really applicable at present. This will be a major challenge in the next few years.
Evaluation of the role of HBV or HCV in some liver diseases: the value of negative PCR tests A negative result with PCR is of significance because of the extreme sensitivity of the test.
HCV AND FULMINANT HEPATITIS
We have evaluated the potential role of PCR in fulminant hepatitis (Table II) . 43 In this study, HCV-RNA was not detected in any patients with fulminant hepatitis of unknown cause. In contrast, HCV-RNA was detected in a significant proportion of patients with HBsAg positive fulminant hepatitis, suggesting coinfection or superinfection by HCV as a potential risk factor. (24- 76 h) cultures of PBMNC. 64 It is also possible to take advantage of the viral genetic variability. For example, sequences of the E2/NS 1 hypervariable region show significant mutations in the same strain when comparing HCV-RNA extracted from tumorous and non-tumorous liver tissue from patients with hepatocellular carcinoma. This means that the positivity of HCV-RNA in the tumour is not due to minute contamination from non-tumorous cells. It also underlines a different rate of replication and mutation in tumorous and non-tumorous liver cells.6' 65 66 PCR for the analysis of HBV and HCV genetic variability: clinical implications HCV The comparison of nucleotide sequences from the published HCV genomes in Japan, USA, and Europe highlights the existence of distinct subtypes of HCV. The 5' non-coding and, to a lesser extent, the core and NS3-NS4 regions of the viral genome are well conserved among different isolates. In contrast, the open reading frames encoding the El and E2/NS 1 envelope proteins are much less conserved. In the 5' part of the E2/NS 1 sequence is located a 'hypervariable' domain (Table III ).65 66 It is possible to take advantage of this 'hypervariable' domain to identify precisely an HCV strain as well as its mutations during follow up. This will be achieved by amplification of the 'hypervariable' domain using primers located on both sides of the E2/NS 1 sequence, followed by nucleotide sequence analysis of the hypervariable domain. 
